FDA Strengthens Safety Label Warnings for Fluoroquinolone Antibiotics
The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
Related News Articles
Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
The AHA Living Learning Network is launching the Quality Exchange, a virtual collaborative for health care quality and patient safety professionals at…
Headline
The U.S. District Court for the Eastern District of Texas March 31 ruled that the Food and Drug Administration does not have the authority to regulate…
Headline
As part of the AHA's Patient Safety Initiative, a dedicated webpage features case studies showing how hospitals and health systems across the nation are…
Blog
During World War II, the U.S. Army Air Corps depended on its B-17 bombers to inflict incredible damage against the Axis powers in Europe. These “Flying…
Headline
Mindy Estes, M.D., former CEO of Saint Luke’s Health System and former AHA board chair, and Nancy Howell Agee, CEO emeritus of Carilion Clinic and former AHA…